Revenue

The aquaculture tech giant posts 41% revenue growth, driven by a 94% surge in its land-based division, signaling a major industry shift.

Japanese giant's all-cash acquisition of Tri Pointe Homes creates a top-5 U.S. builder, raising questions on affordability and market consolidation.

Legrand's plan to repurchase 250,000 shares goes beyond pure financials, signaling a strategic investment in its workforce amid a competitive market.

Capgemini's 2025 results show a strong pivot to AI, with bookings soaring and a €700M plan to reshape its workforce for a new era of tech.

DDPAI's new N5 Pro dashcam combines 4K recording, fail-safe storage, and radar parking mode, aiming to redefine vehicle security and reliability.

As Guardian Pharmacy Services prepares for a key investor conference, it showcases strong growth while its industry faces a looming crisis. Can its model work?

With its Q4 results imminent, the vitamin giant's performance in China and the US will be tested against ambitious goals and shifting global health trends.

As the Milan 2026 Winter Events begin, a massive new e-bike fleet and an affordable 'Champion Pass' aim to redefine sustainable urban mobility.

Canada's largest P&C insurer swaps old debt for new capital, a strategic move to cut costs, enhance flexibility, and fuel its global expansion strategy.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

As Global Sources announces its 2026 Vietnam fair, the event underscores the nation's pivotal role and the shift towards direct, transparent sourcing.

Tokyo's premier contemporary art event explores the theme of time with 21 artists, AI installations, and a subway exit 250 meters in the sky.

A landmark $30M ADB loan to GCash's lending arm aims to bridge a critical financing gap for small businesses and women entrepreneurs in the Philippines.

Fermi America's plan to revive nuclear power for AI's energy needs with a massive Texas campus faces past industry failures and new legal scrutiny.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

FDA approval for new 6- and 24-count NARCAN packs aims to streamline distribution for first responders and public health groups on the front lines.

The firm behind a controversial drug-permissive sporting event is hitting Wall Street via a SPAC, challenging the ethics of global anti-doping standards.

Home prices see modest gains, but rising incomes and balanced inventory are shifting the power back to homebuyers for the first time since the pandemic.

Tucows announced a new $40M stock buyback, but investor concerns over its strategic pivot and debt overshadow the move, pushing shares lower.

Vitalist reports soaring losses and a $6.4M debt surge, raising 'going concern' alarms. Can its new Reebok smartwatches and VitalOS™ platform save it?